Vijaya Diagnostic Centre working capital

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

18.94×	18.94×	21.78×	20.17×	19.60×	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
7.98×	7.98×	8.30×	8.57×	7.65×
136.27×	136.27×	142.28×	169.19×	152.97×
−109.35×	−109.35×	−112.20×	−140.45×	−125.72×
4.33×	4.11×	4.71×	3.96×	2.19×
0.59×	0.59×	0.60×	0.60×	0.59×
1.56×	1.56×	1.56×	1.53×	1.93×
0.80×	0.80×	0.82×	0.83×	0.90×

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIJAYA₹1,464.20

Vijaya Diagnostic Centre Ltd.

· Pharma & Health

₹ CrorePeersTHYROCARE METROPOLIS LALPATHLAB RAINBOW POLYMED PFIZER ONESOURCE KIMSMcap ₹15,066 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Inventory Days (DIO)	19.60	20.17	21.78	18.94	18.94
Receivable Days (DSO)	7.65	8.57	8.30	7.98	7.98
Payable Days (DPO)	152.97	169.19	142.28	136.27	136.27
Cash Conversion Cycle (days)	-125.72	-140.45	-112.20	-109.35	-109.35
Working Capital Turnover	2.19	3.96	4.71	4.11	4.33
Asset Turnover	0.59	0.60	0.60	0.59	0.59
Cash Conversion (CFO/Net Income)	1.93	1.53	1.56	1.56	1.56
CFO/EBITDA	0.90	0.83	0.82	0.80	0.80

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.